Back

LINE-1 expression in cancer correlates with DNA damage response, copy number variation, and cell cycle progression

McKerrow, W. H.; Wang, X.; Mita, P.; Cao, S.; Grivainis, M.; Ding, L.; LaCava, J.; Boeke, J.; Fenyö, D. H.

2020-06-27 cancer biology
10.1101/2020.06.26.174052 bioRxiv
Show abstract

ABSTRACTRetrotransposons are genomic DNA sequences that are capable of copying themselves to new genomic locations via RNA intermediates; LINE-1 is the only retrotransposon that remains autonomous and active in the human genome. The mobility of LINE-1 is largely repressed in somatic tissues, but LINE-1 is active in many cancers. Recent studies using LINE-1 constructs indicate that host cells activate a DNA damage response (DDR) to repair retrotransposition intermediates and resolve conflicts between LINE-1 and DNA replication. Using multi-omic data from the CPTAC project, we found correlations between LINE-1 expression and ATM-MRN-SMC DDR signalling in endometrial cancer and between LINE-1 and the ATR-CHEK1 pathway in p53 wild type breast cancer. This provides evidence that conflicts between LINE-1 and DNA replication occur in at least some human cancers. Furthermore, LINE-1 expression in these cancers is correlated with the total amount of copy number variation genome wide, indicating that, when active in cancer, pointing to a direct impact of LINE-1 associated DNA damage on genome structure. We also find that, in endometrial and ovarian cancer, LINE-1 expression is correlated with the expression of genes that drive cycle progression including E2F3, PLK1 and Aurora kinase B. This study provides evidence, supporting recent work in model cell lines, of a LINE-1/DDR connection in human tumors and raises the possibility of additional interactions between LINE-1 and the cell cycle.Competing Interest StatementThe authors have declared no competing interest.View Full Text

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
eLife
5828 papers in training set
Top 2%
19.0%
2
NAR Cancer
37 papers in training set
Top 0.1%
13.0%
3
Cell Reports
1498 papers in training set
Top 6%
5.7%
4
Cancer Research Communications
51 papers in training set
Top 0.1%
5.3%
5
iScience
1154 papers in training set
Top 3%
5.0%
6
Molecular Cancer Research
49 papers in training set
Top 0.3%
3.5%
50% of probability mass above
7
Disease Models & Mechanisms
119 papers in training set
Top 0.5%
3.3%
8
Scientific Reports
3612 papers in training set
Top 41%
2.5%
9
EMBO Reports
263 papers in training set
Top 3%
2.0%
10
Cancers
213 papers in training set
Top 3%
2.0%
11
Genome Research
468 papers in training set
Top 3%
1.8%
12
Cancer Research
130 papers in training set
Top 2%
1.8%
13
Cell Reports Medicine
153 papers in training set
Top 2%
1.8%
14
Nucleic Acids Research
1281 papers in training set
Top 9%
1.7%
15
Biology Open
156 papers in training set
Top 2%
1.4%
16
Life Science Alliance
285 papers in training set
Top 4%
1.4%
17
Molecular Systems Biology
162 papers in training set
Top 2%
1.2%
18
Oncogene
85 papers in training set
Top 1%
1.2%
19
Molecular Oncology
55 papers in training set
Top 1%
1.1%
20
Open Biology
106 papers in training set
Top 1%
1.0%
21
PLOS Genetics
862 papers in training set
Top 11%
0.9%
22
Cell Genomics
172 papers in training set
Top 4%
0.9%
23
Nature Communications
5641 papers in training set
Top 55%
0.9%
24
International Journal of Molecular Sciences
494 papers in training set
Top 14%
0.9%
25
PeerJ
308 papers in training set
Top 12%
0.6%
26
International Journal of Cancer
49 papers in training set
Top 1%
0.6%
27
NAR Genomics and Bioinformatics
242 papers in training set
Top 5%
0.6%
28
PLOS ONE
5266 papers in training set
Top 63%
0.6%